Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04562155




Registration number
NCT04562155
Ethics application status
Date submitted
18/09/2020
Date registered
24/09/2020
Date last updated
18/08/2022

Titles & IDs
Public title
Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough
Scientific title
Randomized, Double-blind, Parallel Group, Phase 2b Dose-finding, Efficacy and Safety Study of 12-week Twice Daily Oral Administration of BAY 1817080 Compared to Placebo in the Treatment of Refractory and/or Unexplained Chronic Cough (RUCC)
Secondary ID [1] 0 0
2019-004169-42
Secondary ID [2] 0 0
20393
Universal Trial Number (UTN)
Trial acronym
PAGANINI
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Refractory and/or Unexplained Chronic Cough 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BAY1817080
Treatment: Drugs - Placebo

Experimental: BAY1817080 dose A BID - Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.

Experimental: BAY1817080 dose B BID - Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.

Experimental: BAY1817080 dose C BID - Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.

Placebo comparator: Placebo - Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.


Treatment: Drugs: BAY1817080
Study drug BAY1817080 will be administered orally as tablet.

Treatment: Drugs: Placebo
Matching Placebo for BAY1817080 will be administered orally as tablet.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in 24-hour Cough Count After 12 Weeks of Intervention
Timepoint [1] 0 0
From baseline up to 12 weeks
Secondary outcome [1] 0 0
Percentage of Participants With a =30% Reduction From Baseline in 24-hour Cough Count After 12 Weeks of Intervention
Timepoint [1] 0 0
From baseline up to 12 weeks
Secondary outcome [2] 0 0
Change From Baseline in 24-hour Cough Count After 2, 4, and 8 Weeks of Intervention
Timepoint [2] 0 0
From baseline up to 2 weeks, 4 weeks and 8 weeks
Secondary outcome [3] 0 0
Change From Baseline in Awake Cough Frequency Per Hour After 2, 4, 8 and 12 Weeks of Intervention
Timepoint [3] 0 0
From baseline up to 2 weeks, 4 weeks, 8 weeks and 12 weeks
Secondary outcome [4] 0 0
Change From Baseline in Cough Related Quality of Life After 12 Weeks of Intervention
Timepoint [4] 0 0
From baseline up to 12 weeks
Secondary outcome [5] 0 0
Change From Baseline in Cough Severity After 12 Weeks of Intervention
Timepoint [5] 0 0
From baseline up to 12 weeks
Secondary outcome [6] 0 0
Percentage of Participants With a =30 Scale Units Reduction From Baseline After 12 Weeks of Intervention
Timepoint [6] 0 0
From baseline up to 12 weeks
Secondary outcome [7] 0 0
Percentage of Participants With a =1.3-point Increase From Baseline After 12 Weeks of Intervention
Timepoint [7] 0 0
From baseline up to 12 weeks
Secondary outcome [8] 0 0
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Associated Severity
Timepoint [8] 0 0
From the start of study intervention administration until 14 days after the last study medication intake, with an average of 80.0 + 14 days

Eligibility
Key inclusion criteria
* Adults = 18 years of age at the time of signing the informed consent.
* A cough that has lasted for at least 12 months (unresponsive to treatment options) with a diagnosis of refractory chronic cough and/or idiopathic (unexplained) chronic cough.
* Persistent cough for at least the last 8 weeks before screening.
* Women of childbearing potential must agree to use acceptable effective or highly effective birth control methods during the study and for at least 30 days after the last dose.
* Capable of giving signed informed consent.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Smoking history within the last 12 months before screening (all forms of smoking, including e-cigarettes, cannabis and others), and any former smoker with more than 20 pack-years.
* Ongoing or previous exposure to inhalational toxic fumes (e.g., ammonia, chlorine, nitrogen dioxide, phosgene and sulfur dioxide) within the last 12 months before screening.
* Respiratory tract infection within 4 weeks before screening.
* History of chronic bronchitis.
* Systolic blood pressure = 160 mmHg and/or diastolic blood pressure = 100 mmHg at screening visit.
* Positive SARS-CoV-2 virus RNA and/or serology IgG tests at screening visit.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/10/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
23/07/2021
Sample size
Target
Accrual to date
Final
310
Recruitment in Australia
Recruitment state(s)
NSW,SA,WA
Recruitment hospital [1] 0 0
Macquarie University Hospital - Macquarie University
Recruitment hospital [2] 0 0
Maroubra Medical Centre - Maroubra
Recruitment hospital [3] 0 0
Holdsworth House Medical Practice - Sydney
Recruitment hospital [4] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [5] 0 0
Western Respiratory Trial Specialists - Spearwood
Recruitment postcode(s) [1] 0 0
2109 - Macquarie University
Recruitment postcode(s) [2] 0 0
2035 - Maroubra
Recruitment postcode(s) [3] 0 0
2010 - Sydney
Recruitment postcode(s) [4] 0 0
5000 - Adelaide
Recruitment postcode(s) [5] 0 0
6163 - Spearwood
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Maryland
Country [4] 0 0
United States of America
State/province [4] 0 0
Minnesota
Country [5] 0 0
United States of America
State/province [5] 0 0
Montana
Country [6] 0 0
United States of America
State/province [6] 0 0
Tennessee
Country [7] 0 0
United States of America
State/province [7] 0 0
Texas
Country [8] 0 0
United States of America
State/province [8] 0 0
Washington
Country [9] 0 0
Argentina
State/province [9] 0 0
Buenos Aires
Country [10] 0 0
Argentina
State/province [10] 0 0
Ciudad Auton. De Buenos Aires
Country [11] 0 0
Argentina
State/province [11] 0 0
Tucuman
Country [12] 0 0
Belgium
State/province [12] 0 0
Erpent
Country [13] 0 0
Belgium
State/province [13] 0 0
Gent
Country [14] 0 0
Belgium
State/province [14] 0 0
Leuven
Country [15] 0 0
Belgium
State/province [15] 0 0
Liege
Country [16] 0 0
Belgium
State/province [16] 0 0
Mechelen
Country [17] 0 0
Canada
State/province [17] 0 0
Ontario
Country [18] 0 0
Canada
State/province [18] 0 0
Quebec
Country [19] 0 0
Czechia
State/province [19] 0 0
Kralupy nad Vltavou
Country [20] 0 0
Czechia
State/province [20] 0 0
Olomouc
Country [21] 0 0
Czechia
State/province [21] 0 0
Praha 4
Country [22] 0 0
Czechia
State/province [22] 0 0
Teplice
Country [23] 0 0
Czechia
State/province [23] 0 0
Varnsdorf
Country [24] 0 0
France
State/province [24] 0 0
Paris
Country [25] 0 0
France
State/province [25] 0 0
TOULOUSE Cedex 9
Country [26] 0 0
Germany
State/province [26] 0 0
Baden-Württemberg
Country [27] 0 0
Germany
State/province [27] 0 0
Hessen
Country [28] 0 0
Germany
State/province [28] 0 0
Niedersachsen
Country [29] 0 0
Germany
State/province [29] 0 0
Sachsen
Country [30] 0 0
Germany
State/province [30] 0 0
Berlin
Country [31] 0 0
Hungary
State/province [31] 0 0
Balassagyarmat
Country [32] 0 0
Hungary
State/province [32] 0 0
Budapest
Country [33] 0 0
Hungary
State/province [33] 0 0
Godollo
Country [34] 0 0
Hungary
State/province [34] 0 0
Pecs
Country [35] 0 0
Hungary
State/province [35] 0 0
Szazhalombatta
Country [36] 0 0
Italy
State/province [36] 0 0
Lombardia
Country [37] 0 0
Italy
State/province [37] 0 0
Toscana
Country [38] 0 0
Italy
State/province [38] 0 0
Veneto
Country [39] 0 0
Japan
State/province [39] 0 0
Aichi
Country [40] 0 0
Japan
State/province [40] 0 0
Fukui
Country [41] 0 0
Japan
State/province [41] 0 0
Fukuoka
Country [42] 0 0
Japan
State/province [42] 0 0
Hokkaido
Country [43] 0 0
Japan
State/province [43] 0 0
Ishikawa
Country [44] 0 0
Japan
State/province [44] 0 0
Kanagawa
Country [45] 0 0
Japan
State/province [45] 0 0
Mie
Country [46] 0 0
Japan
State/province [46] 0 0
Shizuoka
Country [47] 0 0
Japan
State/province [47] 0 0
Tokyo
Country [48] 0 0
Japan
State/province [48] 0 0
Fukushima
Country [49] 0 0
Netherlands
State/province [49] 0 0
Noord-Brabant
Country [50] 0 0
Netherlands
State/province [50] 0 0
Zwolle
Country [51] 0 0
Poland
State/province [51] 0 0
Bialystok
Country [52] 0 0
Poland
State/province [52] 0 0
Bychawa
Country [53] 0 0
Poland
State/province [53] 0 0
Lublin
Country [54] 0 0
Poland
State/province [54] 0 0
Ostrowiec Swietokrzyski
Country [55] 0 0
Poland
State/province [55] 0 0
Strzelce Opolskie
Country [56] 0 0
Russian Federation
State/province [56] 0 0
Kemerovo
Country [57] 0 0
Russian Federation
State/province [57] 0 0
Moscow
Country [58] 0 0
Russian Federation
State/province [58] 0 0
Novosibirsk
Country [59] 0 0
Russian Federation
State/province [59] 0 0
Samara
Country [60] 0 0
Russian Federation
State/province [60] 0 0
St. Petersburg
Country [61] 0 0
Russian Federation
State/province [61] 0 0
Voronezh
Country [62] 0 0
Slovakia
State/province [62] 0 0
Bardejov
Country [63] 0 0
Slovakia
State/province [63] 0 0
Humenne
Country [64] 0 0
Slovakia
State/province [64] 0 0
Kezmarok
Country [65] 0 0
Slovakia
State/province [65] 0 0
Poprad
Country [66] 0 0
Slovakia
State/province [66] 0 0
Topolcany
Country [67] 0 0
Spain
State/province [67] 0 0
A Coruña
Country [68] 0 0
Spain
State/province [68] 0 0
Barcelona
Country [69] 0 0
Taiwan
State/province [69] 0 0
Keelung
Country [70] 0 0
Taiwan
State/province [70] 0 0
New Taipei City
Country [71] 0 0
Taiwan
State/province [71] 0 0
Taichung
Country [72] 0 0
Taiwan
State/province [72] 0 0
Taipei
Country [73] 0 0
Turkey
State/province [73] 0 0
Antalya
Country [74] 0 0
Turkey
State/province [74] 0 0
Istanbul
Country [75] 0 0
Turkey
State/province [75] 0 0
Izmir
Country [76] 0 0
Turkey
State/province [76] 0 0
Maltepe
Country [77] 0 0
Turkey
State/province [77] 0 0
Mersin
Country [78] 0 0
United Kingdom
State/province [78] 0 0
Tyne And Wear
Country [79] 0 0
United Kingdom
State/province [79] 0 0
Bristol
Country [80] 0 0
United Kingdom
State/province [80] 0 0
Cottingham
Country [81] 0 0
United Kingdom
State/province [81] 0 0
London
Country [82] 0 0
United Kingdom
State/province [82] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bayer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Researchers in this study want to find the optimal therapeutic dose of drug BAY1817080 for patients with long-standing cough with or without clear causes (refractory and/or unexplained chronic cough, RUCC). Study drug BAY1817080 is a new drug under development for the treatment of long-standing cough. It blocks proteins that are expressed by the airway sensory nerves which are oversensitive in patients with long-standing cough. This prevents the urge to cough. Researchers also want to learn the safety of the study drug and how well it works in reducing the cough frequency, severity and urge-to-cough.

Participants in this study will receive either the study drug or placebo (a placebo looks like the test drug but does not have any medicine in it) tablets twice daily for 12 weeks. Observation for each participant will last about 18 weeks in total. Participants will be asked to wear a digital device to record the cough and to complete questionnaires every day to document the symptoms. Blood samples will be collected from the participants to monitor the safety and measure the blood level of the study drug.
Trial website
https://clinicaltrials.gov/study/NCT04562155
Trial related presentations / publications
Fletcher MC. Selectivity of the P2X3 receptor antagonist Eliapixant, and its potential use in the treatment of endometriosis. Purinergic Signal. 2022 Mar;18(1):1-3. doi: 10.1007/s11302-021-09831-5. Epub 2022 Jan 3. No abstract available.
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04562155